

Resource Summary Report

Generated by [RRID](#) on Aug 21, 2026

[shYAP1 # 2](#)

RRID:Addgene_42541

Type: Plasmid

Proper Citation

RRID:Addgene_42541

Plasmid Information

URL: <http://www.addgene.org/42541>

Proper Citation: RRID:Addgene_42541

Insert Name: YAP1

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:23245941](#)

Vector Backbone Description: Backbone Marker:TRC; Backbone Size:8000; Vector Backbone:pLKO.1; Vector Types:Mammalian Expression, Lentiviral, RNAi; Bacterial Resistance:Ampicillin

Comments: TRCN0000107265

Plasmid Name: shYAP1 # 2

Record Creation Time: 20220422T222219+0000

Record Last Update: 20260815T081455+0000

Ratings and Alerts

No rating or validation information has been found for shYAP1 # 2.

No alerts have been found for shYAP1 # 2.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mannion AJ, et al. (2024) Regulation of YAP Promotor Accessibility in Endothelial Mechanotransduction. *Arteriosclerosis, thrombosis, and vascular biology*, 44(3), 666.

Cui H, et al. (2023) Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip. *Advanced healthcare materials*, 12(24), e2300591.

Fallah S, et al. (2021) Src family kinases inhibit differentiation of intestinal epithelial cells through the Hippo effector YAP1. *Biology open*, 10(11).

Uneda A, et al. (2021) Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration. *Acta neuropathologica communications*, 9(1), 29.

Fallah S, et al. (2020) The Hippo Pathway Effector YAP1 Regulates Intestinal Epithelial Cell Differentiation. *Cells*, 9(8).

Lin S, et al. (2019) The mitochondrial deoxyguanosine kinase is required for cancer cell stemness in lung adenocarcinoma. *EMBO molecular medicine*, 11(12), e10849.

Zhao X, et al. (2017) A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. *Cancer letters*, 402, 61.

Fullenkamp CA, et al. (2016) TAZ and YAP are frequently activated oncoproteins in sarcomas. *Oncotarget*, 7(21), 30094.

Ramesh M, et al. (2015) A novel phosphatidic acid-protein-tyrosine phosphatase D2 axis is essential for ERBB2 signaling in mammary epithelial cells. *The Journal of biological chemistry*, 290(15), 9646.